ABSTRACT
Background The purpose of this study was to evaluate the necessity of COVID-19 vaccination in persons with prior COVID-19.
Methods Employees of Cleveland Clinic working in Ohio on Dec 16, 2020, the day COVID-19 vaccination was started, were included. Anyone who tested positive for COVID-19 at least once before the study start date was considered previously infected. One was considered vaccinated 14 days after receipt of the second dose of a COVID-19 mRNA vaccine. The cumulative incidence of COVID-19, symptomatic COVID-19, and hospitalizations for COVID-19, were examined over the next 10.5 months.
Results Among the 52238 employees, 4718 (9%) had prior COVID-19 at the start of the study, and 35113 (67%) had received at least two doses of the vaccine by the end of the study. Of the 4284 COVID-19 infections during the study, 3476 (81.1%) occurred in persons who were unvaccinated, and 4263 (99.5%) occurred among those without prior COVID-19. In Cox proportional hazards regression, both prior COVID-19 and vaccination were independently associated with significantly lower risk of COVID-19. Vaccination was associated with lower risk of COVID-19 among those without prior COVID-19 (HR 0.24, 95% CI 0.22–0.26) but not among those with prior COVID-19 (HR 0.86, 95% CI 0.33–2.29).
Conclusions Both previous infection and vaccination provide substantial protection against COVID-19. Vaccination reduces risk of COVID-19 among those without prior COVID-19 but not among those with prior COVID-19, at least not within one year following infection.
Summary Cumulative incidence of COVID-19 over 10.5 months, including the Delta phase, was examined among 52238 employees at Cleveland Clinic. Vaccination was associated with significantly lower risk of COVID-19 among those without prior COVID-19 but not among those with prior COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Cleveland Clinic Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Duration of follow-up is now more than double what it was in the original release (10.5 months instead of 5 months). The follow-up period also encompasses the time when the Delta variant was the predominant circulating strain. In the earlier version we had an unnecessarily restrictive definition for prior infection. The definition required a person to have been infected at least 42 days before the study start date to be considered previously infected. We have corrected this. In this version anyone infected before the study start date was considered previously infected. The earlier version had COVID-19 infection as the outcome. With the longer follow-up, and higher cumulative numbers of cases, we are also able to report on severe COVID-19 and hospitalization for COVID-19 as additional outcomes. We are thankful to members of the public who took the time to read the article and provide constructive feedback.
Data Availability
Add data produced in the present study are available upon reasonable request to the authors.
